| Trial Name |
Candidate Vaccine |
Location |
Population |
Outcome |
References |
| Vax 004 |
AIDSVAX B/B |
USA |
MSM, high risk women |
No efficacy |
[43,44,76,77] |
| Vax 003 |
AIDSVAX B/E |
Thailand |
IV drug users |
No efficacy |
[45] |
| HVTN 502 / STEP |
MRK Ad5 gag/pol/nef B |
Australia, Caribbean, the Americas |
MSM, high risk men and women |
No protection, transient increased risk. Study terminated early |
[60,78-81] |
| HVTN 503 / Phambili |
MRK Ad5 gag/pol/nef B |
South Africa |
Men and women |
Study terminated due to STEP trial findings. Post-hoc analysis indicating increased risk with vaccine |
[61,62] |
| HVTN 505 |
VRC DNA/rAd5 |
USA |
Circumcised men and MTF transgender |
Stopped for futility, participants are being monitored |
[63] |
| RV 144 |
ALVAC / AIDSVAX B/E |
Thailand |
General Public |
31% protection against HIV infection, no effect on plasma viral load |
[7,69-75,82-85] |
|
